AIG Pharmaceuticals is a growing Pharmaceutical company that was established in 2010 with its headquarters located in Cairo  and Delta with the objective of providing high quality and innovative products to the Egyptian market .In 2011, after 9 years of operations, AIG has grown from a small local company to a market leader of approximately 500 customers .Our factory was established in year 2017 in Badr City. The plant has been constructed according to the broad outlines and principles of the GMP and GLP.We are a company that offers a diversified product range focused on pharmaceutical, cosmeceuticals and herbal drugs.Safety, quality and efficacy of our products and services are the core considerations for the way we do our business putting the customer at the heart of our business.

AIG is a performance-oriented company where our employees are the company’s strongest talent. Their commitment, dedication and aspiration help create a fast moving, goal-oriented atmosphere and with their hard work we were able to make our company a successful entity year after year.In our company we strongly believe that motivation of our employees is an important value, since their motivation and giving them the tools to succeed in a supportive environment helps to drive creativity and performance getting us closer to achieving our goals.We have the strong sales team composed of 40 well expert medical representatives and forcust at 2020 reach to 180 medical representative in egypt; covering pharmacies, hospitals, beauty centers and clinics. They are well supported by a professional marketing team aiding them to sell and position our products in the best support by well-organized and prepared marketing campaigns.The highest of professionalism is maintained by the highest code of ethics and the frequent and regular training programs.

Our Pharmaceuticals business has a broad portfolio of innovative and established medicines. We currently focus on developing new medicines in respiratory and HIV/infectious diseases, oncology and immuno-inflammation; with discovery research exploring these and other areas.


The business is made up of innovative and established medicines and holds leading market positions in respiratory disease and HIV. In our Pharmaceuticals R&D organisation, almost 80% of research spending focuses on two current therapy areas: respiratory and HIV/infectious diseases; and two potential areas: oncology and immuno-inflammation.
Our marketplace

Our strategy is to research and produce innovative, high-quality and needed medicines; making these as accessible as possible to countries at all levels of income and development.

To do this we focus on creating a strong differentiated pipeline, leading in HIV and respiratory, and developing our presence in speciality therapy areas, including oncology and immuno-inflammation.